Multi-functional echogenic immunoliposomes for directed stem cell delivery to atheroma

• US 10,639,277 B1
• Filed: 02/02/2018
• Issued: 05/05/2020
• Est. Priority Date: 03/27/2009
• Status: Active Grant

• Current Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Original Assignee: Board of Regents of the University of Texas System (University of Texas System)
• Inventors: Geng, Yong-Jian, McPherson, David D., Klegerman, Melvin E.
• Primary Examiner(s): Kelly, Robert M
• Application Number:
  US15/887,316
• Time in Patent Office: 823 Days
• Field of Search: None
• CPC Class Codes: A61K 9/0009 involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis microelectromechanical systems A61K9/0097
• CPC Class Codes: A61K 9/1271 Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers liposome as conjugate A61K47/6911
• CPC Class Codes: G01N 33/5047 Cells of the immune system

Abstract

Disclosed are multifunctional-echogenic immunoliposome (MF-ELIP) constructs and compositions, and their methods of use to deliver attached stem cells to a target tissue such as atheroma, to enhance one or more of survival, growth, migration, activity and differentiation of the targeted stem cells, for treating, deterring or preventing mammalian atheroma and coronary artery disease.

Claims

1. A method of treating atherosclerosis in a patient, wherein said treating comprises:

delivering to an atherosclerotic lesion;

(i) a CD34-positive stem cell; and

(ii) an echogenic liposome comprising;

(a) at least one ultrasound reflective material; and

(b) at least a first and second antibody attached to said liposome, wherein said first antibody is an anti-CD34 antibody that binds to the CD34 on the CD34-positive stem cell, wherein said second antibody is an anti-ICAM antibody that localizes said liposome to said atherosclerotic lesion, and wherein said liposome responds to an ultrasound stimulus, thereby localizing said CD34-positive stem cell to said lesion and stabilizing said lesion,

wherein said liposome is formulated to release a stem cell enhancing agent selected from the group consisting of;

antibodies, drugs, genes, and combinations thereof, in response to an ultrasound releasing stimulus.

2. The method of claim 1, wherein said echogenic liposome further comprises a third antibody attached to said liposome, wherein said third antibody recognizes an antigenic determinant on said atherosclerotic lesion or said stem cell, and wherein said antigenic determinant is selected from the group consisting of:

CD146, chemokine receptors, CD140, CD144, PDGF receptor, CD133, CD13, CD29, CD44, CD90, sca-1, VEGF receptor 1, c-kit, stem cell growth factors, SDF, TNF alpha and beta, insulin like growth factor-1, clusterin, intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1), fibrin, integrins, vascular endothelial growth factors (VEGF, including, but not limited to, species A-D and VEGF-A isoforms 110, 120 or 121, 164 or 165, 188 or 189 and

     206), tissue factor, smooth muscle cell myosins and actins, matrix metaloproteinases (MMPs), E-selectin and P-selectin, insulin-like growth factor-1 receptor (IGF-1R), von Willebrand'"'"'s factor and macrophage markers (for example AM-3K, 7C3, 25F9, 27E10), carboxypeptidase M (CPM), cathepsin K, chitotriosidase, CD14, CD68 (Ki-M7, Y2/131, Y1/82A, EBM11), CD163, CD163 soluble (sCD163), CSF-1R (colony-stimulating factor-1 receptor), ED-1, ED-2, ED-3, EMR1, F4/80, Factor XIII-A, ferritin, HAM-56, Ki-M1P, lysozyme M, MAC-1/MAC-3, Myeloid-related protein (MRP) 14, RFD7/RFD9, RM3/1, scavenger receptors (ScR), CD36, ScR-I/II, chemokine receptors (CXCR4, MCP-1) receptors, CD18, and TNF receptors (R1/R2).

3. The method of claim 2, wherein said antigenic determinant is CXCR4 or SDF-1 receptor.

4. The method of claim 2, wherein said third antibody-antigenic determinant recognition blocks the binding of a marker on said atherosclerotic lesion, wherein blocking of said marker enhances a function selected from the group consisting of:

stem cell survival;

stimulation of said atherosclerotic lesion to express a factor that increases survival of the stem cell;

stimulation of said atherosclerotic lesion to express a factor that increases activity of the stem cell;

stimulation of said atherosclerotic lesion to express a factor that increases differentiation of the stem cell; and

combinations thereof.

5. The method of claim 1, wherein said stem cell enhancing agent is further selected from the group consisting of:

c-kit, clusterin (ApoJ), erythropoietin, tetracycline, statins, caspase inhibitors, losartan potassium, ubiquitin, and combinations thereof.

6. The method of claim 1, wherein said stem cell enhancing agent improves the microenvironment of a lesion-bound construct to enhance stem cell survival and differentiation.

7. The method of claim 1, further comprising:

delivering said echogenic liposome to said lesion by an ultrasound-guided catheter through a blood vessel;

measuring by echography to locate said lesion-localized echogenic liposome; and

visualizing said lesion-localized echogenic liposome, wherein said ultrasound-guided catheter delivery comprises imaging ultrasound.